The present invention pertains to the protection against malaria. Moreparticularly, the invention is based on the characterization of a novel liverand sporozoite-stage P. falciparum antigen, referred to as LSA-5. This antigenis highly antigenic and the prevalence of antibodies in subjects living inendemic areas is extremely high (ca. 90 %). The invention concerns antigenicpeptides, mixtures thereof, or polypeptides, mixotopes and conjugatescomprising part of the sequence of LSA-5, as well as immunogenic compositions,vaccines and kits comprising these.
